

TRH: Pathophysiologic and Clinical Implications

C. R. Pickardt¹ and P. C. Scriba²

¹ Medizinische Klinik Innenstadt der Universität München, Federal Republic of Germany

² Klinik für Innere Medizin der Medizinischen Hochschule Lübeck, Federal Republic of Germany

Summary

Thyrotropin releasing hormone is thought to be a tonic stimulator of the pituitary TSH secretion regulating the setpoint of the thyrotrophs to the suppressive effect of thyroid hormones. The peptide stimulates the release of normal and elevated prolactin. ACTH and GH may increase in response to exogenous TRH in pituitary ACTH and GH hypersecretion syndromes and in some extrapituitary diseases.

The pathophysiological implications of extrahypothalamic TRH in humans are essentially unknown.

The TSH response to TRH is nowadays widely used as a diagnostic amplifier in thyroid diseases being suppressed in borderline and overt hyperthyroid states and increased in primary thyroid failure. In hypothyroid states of hypothalamic origin, TSH increases in response to exogenous TRH often with a delayed and/or exaggerated time course.

But in patients with pituitary tumors and suprasellar extension TSH may also respond to TRH despite secondary hypothyroidism. This TSH increase may indicate a suprasellar cause for the secondary hypothyroidism, probably due to portal vessel occlusion. The TSH released in these cases is shown to be biologically inactive.

Keywords: TRH; diagnostic significance; hypothalamic diseases; pituitary failure.

TRH, initially detected and synthesized as the hypothalamic hormone that controls the thyrotrophic activity was found to stimulate the prolactin release in vivo and in vitro^{43, 45, 63, 72, 77}. Moreover, TRH has been shown to be widely distributed over the central nervous system^{36, 37, 44, 71}, where it is believed to have neurotransmitter functions besides the hypophysiotropic effects.

TRH has been detected in the upper gastrointestinal tract¹⁴, where its endogenous functions are unknown. Exogenous TRH inhibits the pentagastrin stimulated gastric secretion¹² and by some degree the glucagon and pancreatic polypeptide release after insulin induced hypoglycemia¹³.

TRH and Thyrotropic Activity

Experimental and pathological disruption of the hypothalamic supply of the pituitary with TRH results in decreased thyroid function⁴⁷, called secondary hypothyroidism. TRH antibodies induce impairment of thyroid function with some effects on the prolactin secretion as well^{28, 32, 39, 76}. But until now, there are no consistent data on the physiological hypothalamo-pituitary relationship in humans. This is due to the fact that serum and urinary TRH is mainly derived from extrahypothalamic sources⁴⁶. In experimental hypo- and hyperthyroidism the hypothalamic content of TRH does not change⁵² arguing against a feedback inhibition between TRH and TSH. There are few studies reporting a decrease of TRH in hyper- and an increase in hypothyroidism with marked differences in the reported normal levels^{29, 50}. Most authors postulate today that TRH is a tonic stimulator of the TSH secretion, modulating the set point of the thyrotrophs to the suppressive effect of thyroid hormones⁴⁷.

TSH responses to TRH are modulated by estrogens in females and in males²⁰. This modulation is due to increasing binding sites of pituitary cells under estrogen influence which can be partly antagonized by thyroid hormones⁴².

Repetitive intravenous and chronic oral TRH administration in euthyroid and hypothyroid individuals results in a decrease of serum TSH^{1, 4, 34, 38, 62, 75} and in euthyroids in an increase of thyroid hormones within the upper normal range^{3, 34, 62}. The TSH decrease following TRH administration was also observed in athyroid patients⁷⁵. The latter finding may be suggestive for down regulation of the TRH receptor of the thyrotrophs which is transient⁶², or for a predominant stimulation of TSH release and a slower de novo synthesis of pituitary TSH³⁸. The simultaneous de-

crease of PRL under these conditions was more pronounced⁵¹.

The thyrotropic activity is under an inhibitory control of somatostatin⁷⁸ and dopamine^{5, 11, 27, 48, 63, 66}, which is more evident in euthyroids, mild and treated hypothyroidism than in severe hypothyroidism^{8, 25}. Dopamine modulates the diurnal variations of TSH^{67, 74}. In states with increased hypothalamic dopamine turnover the tonic inhibition of TSH is thought to be enhanced⁶⁸. This seems to have no clinical implications since oral treatment with dopamine agonists⁴⁰ and antagonists⁸¹ does not influence TSH levels and TSH response to TRH.

TRH and Other Pituitary Hormones

In normal adults TRH does not influence the release of GH and ACTH⁵³. In states with borderline or overt functional disturbances of the GH producing cells, such as active acromegaly^{82, 83}, children with constitutional tall stature and elevated somatomedin levels¹⁷ and in type I diabetes, predominantly in females⁷ and in newborns, when TRH was administered to the mother shortly before delivery⁶⁴, TRH may stimulate GH release. In addition, TRH reduces the somatostatin induced inhibition of GH release in vitro¹⁶.

TRH stimulates prolactin release in normal, hyper- and hypothyroid individuals^{43, 45, 63}. Elevated prolactin levels have been observed in patients with primary hypothyroidism and can be lowered by thyroid hormones. In hyperthyroidism mean prolactin levels are lower as compared to normals and increase during antithyroid treatment⁷². Recently, specific inhibition of prolactin synthesis (decrease of PRL mRNA) by T 3 in vitro was shown⁴⁹.

In normals prolactin is mainly under the inhibitory hypothalamic control and the observed modulation of prolactin secretion by TRH gain clinical significance only in severe hypothyroidism.

In prolactinomas the TRH induced prolactin increase is low with high basal levels of prolactin and vice versa²⁶.

In patients with Cushing's disease⁶¹ TRH may induce a paradoxical rise of ACTH.

Thus, TRH like GnRH may be recognized as a stimulator by non thyrotropic pituitary cells under pathological conditions.

Modulation of the TSH Response to TRH by Non-thyroidal Endocrine and Non-Endocrine Diseases

The TSH response to TRH is nowadays widely used as a diagnostic tool in thyroidology. Therefore, it was

necessary to evaluate factors and hormones which modulate the TSH response in non-thyroidal endocrine and non-endocrine diseases.

In Cushing's syndrome irrespective of the pathogenesis and during glucocorticosteroid pharmacotherapy basal TSH and TSH response may be blunted or suppressed^{21, 41, 54, 73, 84}, and return to normal after successful treatment of hypercortisolism. In Addison's disease moderately elevated basal TSH levels have been observed³.

In patients with active acromegaly blunted TSH response to TRH has been reported^{10, 82} and TSH response may be elevated in GH deficiency¹⁰.

Recently, diminished TSH stimulation has been reported in chronic hypercalcemia and a pronounced increase in hypoparathyroid individuals³³, variations which return to normal after correction of serum calcium levels.

There is an increasing number of data on decreased TSH response to TRH in patients with severe non-thyroidal illness and during total fasting^{35, 70}. The pathogenesis of these disturbances in the TSH responsiveness of the pituitary is not yet well understood. Patients do not exhibit clinical signs of hypothyroidism despite the concomittant development of considerable alterations in the peripheral thyroid hormone metabolism. These phenomena were recently reviewed⁸⁰.

These modulations of the TSH response to TRH in endocrine and non-endocrine diseases have to be kept in mind when using the TRH-test for clinical purposes.

TRH Test in Diagnosis of Hypothalamic and Pituitary Diseases

When TRH became available for clinical investigations, the TRH-test was expected to differentiate between hypothalamic and pituitary origin of central hypothyroidism. Patients with hypothyroidism of obvious hypothalamic origin were shown to have the expected response of TSH to TRH^{31, 56, 58, 69}, which is often delayed and or exaggerated^{19, 22, 23}.

But patients with pituitary tumors, suprasellar extension and visual field impairment exhibited an unexpected TSH response to TRH^{19, 56} which is often delayed and exaggerated as well. The net increment of TSH may not differ from normals or from euthyroid patients with pituitary tumors (Fig. 1).

In none of our patients the TSH-response to TRH was completely absent before pituitary surgery and only in some of them postoperatively^{56, 57}.

Similar data were reported from other groups^{19, 31, 55}. Thus, the failure of TRH test to differentiate

between hypothalamic and pituitary insufficiency was documented.

These findings allow at least two hypothetical explanations. From our data in patients with large pituitary tumors we suggested, that the increase of TSH levels after TRH indicates a suprasellar cause of

subunit in idiopathic central hypothyroidism²⁴. Oral treatment with TRH in one patient resulted in a decrease of the β/α ratio and his thyroid became responsive to the endogenous TRH-stimulated TSH. The authors conclude that TRH may be imperative in the secretion of TSH with full biological potency.




Fig. 1. TSH-response to TRH in patients with pituitary tumors. The upper panel depicts the TSH-response to TRH in 11 euthyroid patients, in the lower panel the TSH-response in 9 hypothyroid patients is demonstrated

secondary hypothyroidism, probably due to a partial occlusion of the portal vessel system, thus preventing the endogenous TRH from reaching the remaining pituitary thyrotrophs^{56, 57, 58, 69}. This explanation was picked up very recently for the recovery of partial pituitary insufficiency after treatment of large inactive pituitary tumors² and for a moderate increase in PRL levels after irradiation of the pituitary in acromegaly⁹.

Faglia and coworkers initially postulated the secretion of a biologically inactive TSH¹⁹. In further investigations they documented an impaired T₃ increase after TRH induced elevation of the TSH levels²² and diminished biological activity of the TSH in a cytochemical bioassay despite immunoidentity to standard TSH²³. More recently, the group published the observation of an elevated ratio of β TSH to α TSH

TRH Test as a Thyroid Function Test

In euthyroid men basal TSH levels as measured by radioimmunoassay are undetectable in about 30%. Thus, by means of basal TSH one can not distinguish suppressed TSH secretion from normal. Therefore, TRH-unresponsiveness of TSH offers more information. The test is nowadays used as an amplifier in cases of borderline hyperthyroidism in "euthyroid" Graves' disease before and after treatment, in cases with autonomous functioning solitary and multiple adenomas and in nodular goiters³⁰. Using the TRH test for routine purposes it became obvious that in our hospital population in 446 patients observed over a period of 12 months TSH suppression was due to preclinical hyperthyroidism in 88 (20%). Out of these about 44% were iodine contaminated. In our area with nutritional iodine deficiency, endemic goiter and an increased prevalence of autonomous adenomas, patients at risk for hyperthyroidism are more easily detected by TRH-test as compared to investigations of the peripheral thyroid hormone levels alone. In this context it may be of interest that in the course of longterm treatment with the antiarrhythmic drug Amiodarone about 30% of bavarian patients developed preclinical hyperthyroidism⁶⁰.

By the combination of TRH stimulation test and the scinti-scans autonomous adenoma⁵⁹ can be classified into different groups depending on the extent of TSH suppression. For economical reasons some European investigators use the test as a first step diagnostic tool.

In primary thyroid failure exaggerated TSH-response may indicate earlier thyroid insufficiency, undetectable by clinical signs, lowered thyroid hormones or elevated basal TSH, a situation found in about 20% of patients with endemic goiter in this area.

Therapeutical Aspects

Experimental investigations of cardiovascular function and survival rates in endotoxic shock gave rise to the conclusion that TRH administered intravenously in high dosages improves the outcome in experimental animal models. In addition, Faden and coworkers observed a significantly better neurological recovery after spine injury in cats¹⁸. They explain these effects by

a partial opiate antagonism of TRH because similar effects occur during treatment with naloxone.

In humans, TRH was found to improve ataxia in patients with spinocerebellar degeneration. Recently, Engel and coworkers¹⁵ reported marked improvement of weakness and spasticity in amyotrophic lateral sclerosis after TRH i. v. The justification for treatment was derived from the observation in animals, where TRH has been detected in nerve endings in the ventral horn of lower motor neurons and in nerve endings in motor nuclear V, VII, XII. In a preliminary study the authors found reduced TRH levels in CSF of patients with amyotrophic lateral sclerosis and other spastic diseases.

Because amyotrophic lateral sclerosis is a progressive disease, these observations prompted us to initiate a pilot study with oral TRH in one patient who is presently under investigation.

References

- Ahuja, S., Baumgarten, S., Oeff, K., Repetitive intravenous TRH-stimulations at short intervals in euthyroid and hypothyroid subjects. *Acta Endocrinol. (Kbh)* 93 (1980), 20—24.
- Arafah, B. M., Brodkey, J. S., Manni, A., Velasco, M. E., Kaufmann, B., Pearson, O. H., Recovery of pituitary function following surgical removal of large nonfunctioning pituitary adenomas. *Clinical Endocrinol.* 17 (1982), 213—222.
- Barnett, A. H., Donald, R. A., Espiner, E. A., High concentrations of thyroid stimulating hormone in untreated glucocorticoid deficiency: Indication of primary hypothyroidism? *Brit. med. J.* 285 (1982), 172—173.
- Benkert, O., Horn, K., Pickardt, C. R., Schmid, D., Sexual impotence: Studies on the hypothalamic pituitary thyroid axis and the effect of oral thyrotropin releasing factor. *Arch. Sex. Behav.* 5 (1976), 275—281.
- Burrow, G. N., May, P. B., Spaulding, S. W., Donabedian, R. K., TRH and dopamine interactions affecting pituitary hormone secretion. *J. Clin. Endocrinol. Metab.* 45 (1977), 65—72.
- Carr, C., Gomez-Pan, A., Weightman, D. R., Roy, V. C. M., Hall, R., Besser, G. M., Thorner, M. O., McNeilly, A. S., Schally, A. V., Kastin, A. J., Coy, D. H., Growth hormone release inhibiting hormone: Action on thyrotropin and prolactin secretion after thyrotrophin releasing hormones. *Brit. med. J.* 3 (1975), 67—69.
- Ceda, G. P., Speroni, G., Dall'Aglio, E., Valenti, G., Butturini, U., Nonspecific growth hormone responses to thyrotrophin releasing hormone in insulin-dependent diabetes: Sex- and age-related pituitary responsiveness. *J. Clin. Endocrinol. Metab.* 55 (1982), 170—174.
- Chen, H. J., Meites, J., Effects of biogenic amines and TRH on release of prolactin and TSH in the rat. *Endocrinology* 96 (1975), 10—22.
- Clark, A. J. L., Mashiter, K., Goolden, A. W., Joplin, G. F., Hyperprolactinemia after external irradiation for acromegaly. *Clin. Endocrinol.* 17 (1982), 291—295.
- Cobb, W. E., Reichlin, S., Jackson, I. M. D., Growth hormone secretory status is a determinant of the thyrotropin response to thyrotropin releasing hormone in euthyroid patients with hypothalamic pituitary diseases. *J. Clin. Endocrinol. Metab.* 52 (1981), 324—329.
- Cooper, D. S., Klibanski, A., Ridgway, E. C., Dopaminergic modulation of TSH and its subunits: In vivo and in vitro studies. *Clinical Endocrinology* 18 (1983), 265—275.
- Dolva, L. Ø., Hanssen, K. F., Berstad, A., Frey, H. M. M., Thyrotrophin releasing hormone inhibits the pentagastrin stimulated gastric secretion in man, a dose response study. *Clinical Endocrinology* 10 (1979), 281—286.
- Dolva, L. Ø., Hanssen, K. F., Flaten, O., Hanssen, L. E., von Schenck, H., The effect of thyrotrophin-releasing hormone (TRH) on pancreatic hormone secretion in normal subjects. *Acta Endocrinol. (Kbh)* 102 (1983), 224—230.
- Dolva, L. Ø., Hanssen, K. F., Aadland, E., Sand, T., Thyrotropin-releasing hormone immunoreactivity in the gastrointestinal tract of man. *J. Clin. Endocrinol. Metab.* 56 (1983), 524—529.
- Engel, W. K., Siddique, T., Nicoloff, J. T., Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone. *Lancet* 1 (1983), 73—75.
- Enjalbert, A., Epelbaum, J., Arancibia, S., Tapia-Arancibia, L., Bluet-Pajot, M. Th., Kordon, C., Reciprocal interactions of somatostatin with thyrotropin-releasing hormone and vasoactive intestinal peptide on prolactin and growth hormone secretion in vitro. *Endocrinology* 111 (1982), 42—47.
- Evain-Brion, D., Garnier, P., Schimpff, R. M., Chaussain, J. L., Job, J. C., Growth hormone response to thyrotropin-releasing hormone and oral glucose-loading test in tall children and adolescents. *J. Clin. Endocrinol. Metab.* 56 (1983), 429—432.
- Faden, A. I., Jacobs, T. P., Holaday, J. W., Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. *N. Engl. J. Med.* 305 (1981), 1063—1067.
- Faglia, G., Beck-Peccoz, P., Ambrosi, B., Ferrari, C., Neri, V., Prolonged and exaggerated elevations in plasma thyrotropin (HTSH) after thyrotropin releasing factor (TRF) in patients with pituitary tumors. *J. Clin. Endocrinol. Metab.* 33 (1971), 999—1002.
- Faglia, G., Beck-Peccoz, P., Ferrari, C., Ambrosi, B., Spada, A., Travaglini, P., Enhanced plasma thyrotrophin response to thyrotropin releasing hormone following oestradiol administration in man. *Clinical Endocrinology* 2 (1973), 207—210.
- Faglia, G., Ferrari, C., Beck-Peccoz, P., Spada, A., Travaglini, P., Ambrosi, B., Reduced plasma thyrotrophin response to thyrotropin releasing hormone after dexamethasone administration in normal subjects. *Horm. Metab. Res.* 5 (1973), 289—292.
- Faglia, G., Ferrari, C., Paracchi, A., Spada, A., Beck-Peccoz, P., Triiodothyronine response to thyrotropin releasing hormone in patients with hypothalamic-pituitary disorders. *Clinical Endocrinology* 4 (1975), 585—590.
- Faglia, C., Bitensky, L., Pinchera, A., Ferrari, C., Paracchi, A., Beck-Peccoz, P., Ambrosi, B., Spada, A., Thyrotropin secretion in patients with central hypothyroidism: Evidence for reduced biological activity of immunoreactive thyrotropin. *J. Clin. Endocrinol. Metab.* 48 (1979), 989—998.
- Faglia, G., Beck-Peccoz, P., Ballabio, M., Nava, C., Excess of β -subunit of thyrotropin (TSH) in patients with idiopathic central hypothyroidism due to the secretion of TSH with reduced biological activity. *J. Clin. Endocrinol. Metab.* 56 (1983), 908—914.
- Feek, C. M., Sawers, J. S. A., Brown, N. S., Seth, J., Irvine, W. J.,

- Toft, A. D., Influence of the thyroid status on dopaminergic inhibition of thyrotropin and prolactin secretion: Evidence of an additional feedback mechanism in the control of thyroid hormone secretion. *J. Clin. Endocrinol. Metab.* *51* (1980), 585—589.
26. Flückiger, E., del Pozo, E., von Werder, K., Prolactin, physiology, pharmacology and clinical findings. Monographs in Endocrinology *23*. Berlin-Heidelberg-New York: Springer, 1982
 27. Foord, St. M., Peters, J. R., Dieguez, C., Scanlon, M. F., Hall, R., Dopamine receptors on intact anterior pituitary cells in culture: Functional association with the inhibition of prolactin and thyrotropin. *Endocrinology* *112* (1983), 1567—1577.
 28. Fraser, H. M., McNeilly, A. S., Effect of chronic immunoneutralization of thyrotropin releasing hormone on the hypothalamic pituitary thyroid axis, prolactin and reproductive function in the ewe. *Endocrinology* *111* (1982), 1964—1973.
 29. Guignier, F., Pelletier, J. L., Touzery, C., Gailliard, P., Thyrotropin-releasing hormone radioimmunoassay in human serum and its application in thyroïdal pathology. *Eur. J. Nucl. Med.* *6* (1981), 73—78.
 30. Habermann, J., Leisner, B., Witte, A., Pickardt, C. R., Scriba, P. C., Iodine contamination as a cause of hyperthyroidism or lack of TSH response to TRH stimulation (results based on a screening investigation). *J. Endocrinol. Invest.* *5* (1982), 153—156.
 31. Hall, R., Ormston, B. J., Besser, G. M., Cryer, R. J., McKendrick, M., The thyrotrophin-releasing hormone test in diseases of the pituitary and hypothalamus. *Lancet* *I* (1972), 754—763.
 32. Hefco, E., Krulich, L., Aschenbrenner, J. E., Effect of hypothalamic deafferentiation on the secretion of thyrotropin during thyroid blockade and exposure to cold in the rat. *Endocrinology* *97* (1975), 1234—1240.
 33. Hiramatsu, K., Hashizume, K., Aizawa, T., Ichikawa, K., Yamada, T., Thyrotropin secretion in patients with hyperparathyroidism or hypoparathyroidism: Effect of serum calcium on thyrotropin release. *J. Clin. Endocrinol. Metab.* *56* (1983), 623—626.
 34. Horn, K., Erhardt, F., Fahlbusch, F., Pickardt, C. R., von Werder, K., Scriba, P. C., Recurrent goiter, hyperthyroidism, galactorrhea and amenorrhea due to a thyrotropin and prolactin-producing pituitary tumor. *J. Clin. Endocrinol. Metab.* *43* (1976), 137—143.
 35. Hugues, J.-N., Burger, A. G., Grouselle, D., Voirol, M. J., Chabert, P., Modigliani, E., Sebaoun, J., Evidence of a thyrotropin-releasing hormone dependent increase in plasma thyrotropin during refeeding of starved rats. *Endocrinology* *112* (1983), 715—719.
 36. Jackson, J. M. D., Thyrotropin releasing hormone (TRH): Distribution in mammalian species and its functional significance. In: *Thyrotropin Releasing Hormone* (Griffiths, E. C., Bennett, G. W., eds.), pp. 3—18. New York: Raven Press.
 37. Johannsson, O., Hökfelt, T., Jeffcoate, S. L., White, N., Spindel, E., Light and electron microscopic immunohistochemical studies on TRH in the central nervous system of the rat. In: *Thyrotropin Releasing Hormone* (Griffiths, E. C., Bennett, G. W., eds.), pp. 19—32. New York: Raven Press.
 38. Klindt, J., Davis, S. L., Ohlson, D. L., Plasma concentration of thyrotropin-releasing hormone, thyrotropin, prolactin and growth hormone during five-day osmotic pump infusion of thyrotropin-releasing hormone. *Endocrinology* *104* (1979), 45—79.
 39. Koch, Y., Goldhaber, G., Fireman, I., Zor, U., Shani, J., Tal, E., Suppression of prolactin and thyrotropin secretion in the rat by antiserum to thyrotropin-releasing hormone. *Endocrinology* *100* (1977), 1476—1478.
 40. Köbberling, J., Darragh, A., del Pozo, E., Chronic dopamine receptor stimulation using bromocriptine: Failure to modify thyroid function. *Clinical Endocrinology* *11* (1979), 367—370.
 41. Kuku, S. F., Child, D. F., Nader, S., Fraser, T. R., Thyrotrophin and prolactin responsiveness to thyrotrophin releasing hormone in Cushing's disease. *Clinical Endocrinology* *4* (1975), 437—442.
 42. Labrie, F., Drouin, J., Ferlang, L., Lagacé, L., Beaulieu, M., de Léan, A., Kelly, P. A., Caron, M. G., Raymond, V., Mechanism of action of hypothalamic hormones in the anterior pituitary gland and specific modulation of their activity by sex steroids and thyroid hormones. In: *Rec. Progr. Horm. Res.* *34* (1978), 25—93.
 43. Jacobs, L. S., Snyder, P. J., Utiger, R. D., Daughaday, W. H., Prolactin response to thyrotropin-releasing hormone in normal subjects. *J. Clin. Endocrinol. Metab.* *36* (1973), 1069—1070.
 44. Lechan, R. M., Jackson, I. M. D., Immunohistochemical localization of thyrotropin releasing hormone in the rat hypothalamus and pituitary. *Endocrinology* *111* (1982), 55—65.
 45. L'Hermite, M., Vanhaelst, L., Copinschi, G., Leclercq, R., Goldstein, L., Bruno, O. D., Robyn, C., Prolactin release after injection of thyrotrophin releasing hormone in man. *Lancet* *I* (1972), 763—764.
 46. Mallik, T. K., Wilber, J. F., Pegues, J., Measurements of thyrotropin-releasing hormone like material in human peripheral blood by affinity chromatography and radioimmunoassay. *J. Clin. Endocrinol. Metab.* *54* (1982), 1194—1198.
 47. Martin, J. B., Boshans, R., Reichlin, S., Feedback regulation of TSH-secretion in rats with hypothalamic lesions. *Endocrinology* *87* (1970), 1032—1040.
 48. Massara, F., Camanni, F., Amoroso, A., Molinatti, G. M., Müller, E. E., Increased thyrotrophin and prolactin secretion induced by domperidone in hypothyroid subjects. *Acta Endocrinol. (Kbh)* *97* (1981) 48—53.
 49. Maurer, R. A., Thyroid hormone specifically inhibits prolactin synthesis and decreases prolactin messenger ribonucleic acid levels in cultured pituitary cells. *Endocrinology* *110* (1982), 1507—1520.
 50. Mitsuma, T., Hirooka, Y., Nihei, N., Radioimmunoassay of thyrotrophin releasing hormone in human serum and its clinical application. *Acta Endocrinol. (Kbh)* *83* (1976), 225—235.
 51. Mongioi, A., Aliffi, A., Vicari, E., Coniglione, F., Scapagnini, U., D'Agata, R., Down-regulation of prolactin secretion in men during continuous thyrotropin-releasing hormone infusion: Evidence of induction of pituitary desensitization by continuous TRH administration. *J. Clin. Endocrinol. Metab.* *56* (1983), 904—907.
 52. Montoya, E., Seidel, M. J., Wilber, J. F., Thyrotropin-releasing hormone secretory physiology: Studies by radioimmunoassay and affinity chromatography. *Endocrinology* *96* (1975), 1413—1418.
 53. Nilsson, K. O., Thorell, J. I., Hökfelt, D., The effect of thyrotropin releasing hormone on the release of thyrotrophin and other pituitary hormones in man under basal conditions and following adrenergic blocking agents. *Acta Endocrinol. (Kbh)* *76* (1974), 24—34.
 54. Otsuki, M., Dakoda, M., Baba, S., Influence of glucocorticoids on TRH-induced TSH-response in man. *J. Clin. Endocrinol. Metab.* *36* (1973), 95—102.

55. Petersen, V. B., McGregor, A. M., Belchetz, P. E., Elkeles, R. S., Hall, R., The secretion of thyrotrophin with impaired biological activity in patients with hypothalamic-pituitary disease. *Clinical Endocrinology* 8 (1978), 397—402.
56. Pickardt, C. R., Geiger, W., Fahlbusch, R., Scriba, P. C., Stimulation der TSH-Sekretion durch TRF-Belastung bei hypothalamischen und hypophysären Krankheitsbildern. *Klin. Wschr.* 50 (1972), 42—52.
57. Pickardt, C. R., Erhardt, F., Fahlbusch, R., Scriba, P. C., Portal vessel occlusion: A cause for pituitary insufficiency in patients with pituitary tumors? *Europ. J. Clin. Invest.* 3 (1973), 262.
58. Pickardt, C. R., Erhardt, F., Fahlbusch, R., Grüner, J., Scriba, P. C., The diagnostic significance of the stimulation of TSH secretion by thyrotrophin releasing hormone (TRH) administration in diseases of the hypothalamus and pituitary. *Excerpta Med. (Amsterdam) ICS* 306 (1973), 105—107.
59. Pickardt, C. R., Erhardt, F., Grüner, J., Heinze, H. G., Horn, K., Scriba, P. C., Stimulierbarkeit der TSH-Sekretion durch TRH bei autonomen Adenomen der Schilddrüse. *Dtsch. med. Wschr.* 98 (1973), 152—157.
60. Pickardt, C. R., Theisen, F., Witte, A., Leisner, B., Theisen, K., Jahrmärker, H., Effects of long-term treatment with amiodarone on thyroid function and thyroidal iodine concentration. In: *New Aspects in the Medical Treatment of Tachyarrhythmias—Role of Amiodarone* (Breithardt, G., Loogen, F., eds.), pp. 245—248. München-Wien-Baltimore: Urban & Schwarzenberg, 1983.
61. Pieters, G. F. F., Smals, A. G. H., Goverde, H. J. M., Pesman, G. J., Meyer, E., Kloppenborg, P. W. C., Adrenocorticotropin and cortisol responsiveness to thyrotrophin-releasing hormone and luteinizing hormone-releasing hormone discloses two subsets of patients with Cushing's disease. *J. Clin. Endocrinol. Metab.* 55 (1982), 1188—1197.
62. Rabello, M. M., Snyder, P. J., Utiger, R. D., Effects on the pituitary-thyroid axis and prolactin secretion of single and repetitive oral doses of thyrotrophin-releasing hormone (TRH). *J. Clin. Endocrinol. Metab.* 39 (1974), 571—578.
63. Refetoff, S., Fang, V. S., Rapoport, B., Friesen, H. G., Interrelationships in the regulation of TSH and prolactin secretion in man: Effects of L-Dopa, TRH and thyroid hormone in various combinations. *J. Clin. Endocrinol. Metab.* 38 (1974), 450—457.
64. Roti, E., Gnudi, A., Robuschi, G., Emanuele, R., Benassi, L. J., Braverman, L. E., Response of growth hormone to thyrotrophin-releasing hormone during fetal life. *J. Clin. Endocrinol. Metab.* 54 (1982), 1255—1257.
65. Sack, J., Fisher, D. A., Grajwer, L. A., Lam, R. W., Wang, C. C., The response of newborn sheep to TRH with and without somatostatin. *Endocrinology* 100 (1977), 1533—1538.
66. Scanlon, M. F., Weightman, D. R., Shale, D. J., More, B., Heath, M., Snow, M. H., Lewis, M., Hall, R., Dopamine is a physiological regulator of thyrotrophin (TSH) secretion in normal man. *Clin. Endocrinol.* 10 (1979), 7—15.
67. Scanlon, M. F., Wechman, A. D., Lewis, M., Pourmand, M., Rodriguez-Arno, W. D., Weightman, D. R., Hall, R., Dopaminergic modulation of circadian thyrotrophin rhythms and thyroid hormone levels in euthyroid subjects. *J. Clin. Endocrinol. Metab.* 51 (1980), 1251—1256.
68. Scanlon, M. F., Rodriguez-Arno, M. D., McGregor, A. M., Weightman, D., Lewis, M., Cook, D. B., Gomez-Pan, A., Hall, R., Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. *Clinical Endocrinology* 14 (1981), 133—143.
69. Scriba, P. C., Erhardt, F., Heinze, H. G., Horn, K., Marschner, I., Pickardt, C. R., Anterior pituitary and TSH. In: *Regulation of Thyroid Function* (Klein, E., Reinwein, D., eds.), pp. 35—46. Stuttgart-New York: Schattauer, 1976.
70. Scriba, P. C., Bauer, M., Emmert, D., Fateh-Moghadam, A., Hofmann, G. G., Horn, K., Pickardt, C. R., Effects of obesity, total fasting and re-alimentation on L-thyroxine (T₄), 3,5,3',5'-L-triiodothyronine (T₃), 3,3',5'-L-triiodothyronine (rT₃), thyroxine binding globulin (TBG), cortisol, thyrotrophin, cortisol binding globulin (CBG), transferrin, α -2-haptoglobin and complement C'3 in serum. *Acta Endocrinol. (Kbh)* 91 (1979), 629—643.
71. Shambaugh III G. E., Wilber, J. F., Montoya, E., Ruder, H., Blonsky, E. R., Thyrotrophin-releasing hormone (TRH): Measurements in human spinal fluid. *J. Clin. Endocrinol. Metab.* 41 (1975), 131—134.
72. Snyder, P. J., Jacobs, L. S., Utiger, R. D., Daughaday, W. H., Thyroid hormone inhibition of the prolactin response to thyrotrophin-releasing hormone. *J. Clin. Invest.* 52 (1973), 2324—2329.
73. Sowers, J. R., Carlson, H. E., Brautbar, N., Hershman, J. M., Effect of dexamethasone on prolactin and TSH responses to TRH and metoclopramide in man. *J. Clin. Endocrinol. Metab.* 44 (1977), 237—241.
74. Sowers, J. R., Catania, R. A., Hershman, J. M., Evidence for dopaminergic control of circadian variations in thyrotrophin secretion. *J. Clin. Endocrinol. Metab.* 54 (1982), 673—675.
75. Staub, J. J., Girard, J., Mueller-Brand, J., Noelpp, B., Werner-Zodrow, I., Baur, U., Heitz, Ph., Genssenjaeger, E., Blunting of TSH response after repeated oral administration of TRH in normal and hypothyroid subjects. *J. Clin. Endocrinol. Metab.* 46 (1978), 260—266.
76. Szabo, M., Kovathana, N., Gordon, K., Frohman, L. A., Effect of passive immunization with an antiserum to thyrotrophin (TSH)-releasing hormone on plasma TSH levels in thyroidectomized rats. *Endocrinology* 102 (1978), 799—805.
77. Tashjian, A. H., Barowsky, N. J., Jensen, D. K., Thyrotrophin releasing hormone: Direct evidence for stimulation of prolactin production by pituitary cells in culture. *Biochem. Biophys. Res. Comm.* 43 (1971), 516.
78. Urman, S., Critchlow, V., Long term elevations in plasma thyrotrophin but not growth hormone, concentrations associated with lesion-induced depletion of median eminence somatostatin. *Endocrinology* 112 (1983), 659—644.
79. Vale, W., Rivier, C., Brazeau, P., Guillemin, R., Effects of somatostatin on the secretion of thyrotrophin and prolactin. *Endocrinology* 95 (1974), 968—983.
80. Wartofsky, L., Burman, K. D., Alterations in thyroid function in patients with systemic illness: The "euthyroid sick syndrome". *Endocrine Reviews* 3 (1982), 164—217.
81. Wenzel, K. W., Döring, J., Lack of influence of the antidopaminergic drug domperidone on basal and TRH-stimulated TSH-serum levels after oral administration. *Acta Endocrinol. (Kbh)* 101 (1982), 550—554.
82. von Werder, K., Wachstumshormone und Prolaktin. Urban & Schwarzenberg, 1975.
83. von Werder, K., Fahlbusch, R., Gay, R., Pickardt, C. R., Schultz, B., Stimulation der Wachstumshormon- und Prolaktin-Sekretion durch TRH bei Akromegalie. *Klin. Wschr.* 54 (1976), 335.
84. Wilber, J. F., Utiger, R. D., The effect of glucocorticoids on thyrotrophin secretion. *J. Clin. Invest.* 48 (1969), 2096—2103.

Author's address: Dr. C. R. Pickardt, Medizinische Klinik Innenstadt der Universität München, Ziemssenstrasse 1, D-8000 München, Federal Republic of Germany.